Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition

Letters4 December 2018Treatment of Dilated Cardiomyopathy With Interleukin-1 InhibitionGiacomo De Luca, MD, Corrado Campochiaro, MD, Charles A. Dinarello, MD, Lorenzo Dagna, MD, and Giulio Cavalli, MDGiacomo De Luca, MDVita-Salute San Raffaele University and Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy (G.D., C.C., L.D., G.C.)Search for more papers by this author, Corrado Campochiaro, MDVita-Salute San Raffaele University and Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy (G.D., C.C., L.D., G.C.)Search for more papers by this author, Charles A. Dinarello, MDUniversity of Colorado Denver, Aurora, Colorado (C.A.D.)Search for more papers by this author, Lorenzo Dagna, MDVita-Salute San Raffaele University and Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy (G.D., C.C., L.D., G.C.)Search for more papers by this author, and Giulio Cavalli, MDVita-Salute San Raffaele University and Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy (G.D., C.C., L.D., G.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0315 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Dilated cardiomyopathy is a severe, irreversible form of heart disease characterized by left ventricular systolic dysfunction and dilation that are not explained by abnormal loading or coronary artery disease. The current mainstay of treatment is symptomatic management of heart failure and arrhythmia. Novel, effective therapeutic options are an unmet clinical need (1). The central role of inflammation in heart failure is now established, and the heart exhibits a stereotyped inflammatory response to injury that is mediated by interleukin-1. Selective inhibition of this cytokine has thus emerged as an intriguing therapeutic opportunity (2).Objective: To report the results of treatment ...References1. Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail. 2018;20:228-39. [PMID: 29271570] doi:10.1002/ejhf.1103 CrossrefMedlineGoogle Scholar2. Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39:2063-9. [PMID: 29584915] doi:10.1093/eurheartj/ehy128 CrossrefMedlineGoogle Scholar3. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134-44. [PMID: 26209330] doi:10.1093/rheumatology/kev269 CrossrefMedlineGoogle Scholar4. Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med. 2016;44:e751-4. [PMID: 27031379] doi:10.1097/CCM.0000000000001654 CrossrefMedlineGoogle Scholar5. De Luca G, Cavalli G, Campochiaro C, Tresoldi M, Dagna L. Myocarditis: an interleukin-1-mediated disease? Front Immunol. 2018;9:1335. [PMID: 29951067] doi:10.3389/fimmu.2018.01335 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Vita-Salute San Raffaele University and Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy (G.D., C.C., L.D., G.C.)University of Colorado Denver, Aurora, Colorado (C.A.D.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0315.This article was published at Annals.org on 31 July 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byThe Spectrum of COVID-19-Associated Myocarditis: A Patient-Tailored Multidisciplinary ApproachThe Genetic Pathways Underlying Immunotherapy in Dilated CardiomyopathyAnakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac InvolvementCanakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s diseaseInterleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseasesRepurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the PandemicCurrent treatment options and safety considerations when treating adult-onset Still’s diseaseAntiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditisSystemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysisTherapeutic strategies for virus-negative myocarditis: a comprehensive reviewTargeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 PatientsAutophagy and Protein SecretionAutophagy in the regulation of protein secretion in immune cellsEfficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort studyBiologic discontinuation strategies and outcomes in patients with rheumatoid arthritisIL‐1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditisDiagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment on “Antisynthetase syndrome and cardiac involvement: a rare association” by Meudec et al. Joint Bone Spine 2018. doi: 10.1016/j.jbspin.2018.09.019Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective studyAnakinra Therapy for Non-cancer Inflammatory Diseases 4 December 2018Volume 169, Issue 11Page: 819-820KeywordsArrhythmiaBiopsyDilated cardiomyopathyEchocardiographyFibrosisHeart failureInflammationLeft ventricular ejection fractionMagnetic resonance imagingTroponin T ePublished: 31 July 2018 Issue Published: 4 December 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...